PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.

Abstract Tumor epithelial cells (TEpCs) and spindle-shaped stromal cells, not associated with the vasculature, of patients with early breast cancer express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), receptor activator of nuclear factor kappa B ligand, stromal cell derived factor-1, interleukin-6, macrophage colony stimulating factor, chemokine (C-C motif) ligand-2 (CCL-2) and their receptors at significantly higher levels compared with non-neoplastic breast tissues. We evaluated the clinicopathological significance of these ligands and receptors in TEpC and spindle-shaped stromal cells, not associated with the vasculature, to determine their impact on prognosis of patients with early-stage breast cancer.
PMID
Related Publications

Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.

Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines.

Interleukin-6 receptor in spindle-shaped stromal cells, a prognostic determinant of early breast cancer.

Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells.

Authors

Mayor MeshTerms
Keywords

CCR-2

Early breast cancer

Spindle-shaped stromal cells

TRAIL-R3

Tumor epithelial cells

Journal Title bmc cancer
Publication Year Start




PMID- 28420351
OWN - NLM
STAT- In-Process
DA  - 20170419
LR  - 20170423
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 17
IP  - 1
DP  - 2017 Apr 18
TI  - Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial
      cells of patients with early breast cancer.
PG  - 280
LID - 10.1186/s12885-017-3259-8 [doi]
AB  - BACKGROUND: Tumor epithelial cells (TEpCs) and spindle-shaped stromal cells, not 
      associated with the vasculature, of patients with early breast cancer express
      osteoprotegerin (OPG), tumor necrosis factor-related apoptosis-inducing ligand
      (TRAIL), receptor activator of nuclear factor kappa B ligand, stromal cell
      derived factor-1, interleukin-6, macrophage colony stimulating factor, chemokine 
      (C-C motif) ligand-2 (CCL-2) and their receptors at significantly higher levels
      compared with non-neoplastic breast tissues. We evaluated the clinicopathological
      significance of these ligands and receptors in TEpC and spindle-shaped stromal
      cells, not associated with the vasculature, to determine their impact on
      prognosis of patients with early-stage breast cancer. METHODS: We conducted
      immunohistochemical analyses of protein expression in primary tumors of patients 
      with early breast cancer and analyzed their association with standard prognostic 
      parameters and clinical outcomes, including local relapse, metastatic recurrence,
      disease-free survival (DFS), metastasis-free survival (MFS), and overall survival
      (OS). RESULTS: Elevated levels of TRAIL-R3 and chemokine (C-C motif) receptor 2
      (CCR-2) in TEpCs and OPG and CCL-2 in stromal cells were significantly associated
      with a higher risk of metastasis (p = 0.032, p = 0.003, p = 0.038, and p = 0.049;
      respectively). Moreover, high expression of TRAIL-R3 and CCR-2 in TEpCs was
      associated with shorter DFS, MFS, and OS. High TRAIL-R3 expression in TEpCs was
      an independent prognostic factor for DFS and OS, and high CCR-2 expression in
      these cells was an independent prognostic factor for MFS. CONCLUSIONS: High
      levels of TRAIL-R3 and CCR-2 expression in TEpCs identified patients with early
      breast cancer with poor outcomes.
FAU - Labovsky, Vivian
AU  - Labovsky V
AD  - Instituto de Biologia y Medicina Experimental, Laboratorio de Inmunohematologia
      (IBYME) - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, CP 1428, Ciudad Autonoma de Buenos Aires, Argentina.
      [email protected]
FAU - Martinez, Leandro Marcelo
AU  - Martinez LM
AD  - Instituto de Biologia y Medicina Experimental, Laboratorio de Inmunohematologia
      (IBYME) - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, CP 1428, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - Davies, Kevin Mauro
AU  - Davies KM
AD  - Departamento de Anatomia Patologica, Hospital Italiano, Juan Domingo Peron 4190, 
      CP 1181, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - de Lujan Calcagno, Maria
AU  - de Lujan Calcagno M
AD  - Departamento de Bioestadistica, Facultad de Farmacia y Bioquimica, Universidad de
      Buenos Aires, Junin 954, CP 1113, Ciudad Autonoma de Buenos Aires, Buenos Aires, 
      Argentina.
FAU - Garcia-Rivello, Hernan
AU  - Garcia-Rivello H
AD  - Departamento de Anatomia Patologica, Hospital Italiano, Juan Domingo Peron 4190, 
      CP 1181, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - Wernicke, Alejandra
AU  - Wernicke A
AD  - Departamento de Anatomia Patologica, Hospital Italiano, Juan Domingo Peron 4190, 
      CP 1181, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - Feldman, Leonardo
AU  - Feldman L
AD  - Departamento de Trasplante de Medula Osea, Fundacion Favaloro, Solis 443,
      C1078AAI, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - Matas, Ayelen
AU  - Matas A
AD  - Instituto de Biologia y Medicina Experimental, Laboratorio de Inmunohematologia
      (IBYME) - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, CP 1428, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - Giorello, Maria Belen
AU  - Giorello MB
AD  - Instituto de Biologia y Medicina Experimental, Laboratorio de Inmunohematologia
      (IBYME) - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, CP 1428, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - Borzone, Francisco Raul
AU  - Borzone FR
AD  - Instituto de Biologia y Medicina Experimental, Laboratorio de Inmunohematologia
      (IBYME) - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, CP 1428, Ciudad Autonoma de Buenos Aires, Argentina.
FAU - Choi, Hosoon
AU  - Choi H
AD  - Central Texas Veterans Research Foundation, Temple, TX, USA.
FAU - Howard, Scott C
AU  - Howard SC
AD  - University of Tennsseee Health Sciences Center, Memphis, USA.
FAU - Chasseing, Norma Alejandra
AU  - Chasseing NA
AD  - Instituto de Biologia y Medicina Experimental, Laboratorio de Inmunohematologia
      (IBYME) - Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET),
      Vuelta de Obligado 2490, CP 1428, Ciudad Autonoma de Buenos Aires, Argentina.
      [email protected]
LA  - eng
PT  - Journal Article
DEP - 20170418
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
PMC - PMC5395831
OTO - NOTNLM
OT  - CCR-2
OT  - Early breast cancer
OT  - Spindle-shaped stromal cells
OT  - TRAIL-R3
OT  - Tumor epithelial cells
EDAT- 2017/04/20 06:00
MHDA- 2017/04/20 06:00
CRDT- 2017/04/20 06:00
PHST- 2015/12/24 [received]
PHST- 2017/04/04 [accepted]
AID - 10.1186/s12885-017-3259-8 [doi]
AID - 10.1186/s12885-017-3259-8 [pii]
PST - epublish
SO  - BMC Cancer. 2017 Apr 18;17(1):280. doi: 10.1186/s12885-017-3259-8.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>